Loading quotes...

Forecast

Buy	2
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Sinovac extends deadline for special dividend to June 30, 2026

Sinovac has extended the deadline for submitting payment instructions for the announced special cash dividend of $55.00 per common share to June 30, 2026. Eligible shareholders are those registered at the close of trading on May 23, 2025; the original deadline was December 31, 2025. The company, which typically does not pay dividends, shows weak financial condition with a current market capitalization of about $41.15 million; D.F. King & Co. has been named as the information agent. » More on de.investing.com
Sinovac Biotech renews board committees and adjusts governance

After a board meeting, Sinovac Biotech reappointed members to its committees and amended the audit committee’s charter. Simon Anderson and Yuk Lam Lo were appointed to the audit committee, with Anderson as chair; the minimum number of members was reduced from three to two. Andrew Yan, Shan Fu and Yuk Lam Lo make up the remuneration committee, with Lo as chair; the nomination and governance committee consists of Andrew Yan, Yumin Qiu and Yu Wang, with Yan as chair. A legal committee was also established to review claims in certain court proceedings, comprising Andrew Yan (chair) and Yuk Lam Lo. As a foreign private issuer, the company follows the rules of its home jurisdiction, which permits the reduction in audit committee membership. » More on de.investing.com
Sinovac receives conditional approval to remain on NASDAQ

The Chinese vaccine maker Sinovac has received conditional approval from the Nasdaq Hearings Panel to remain listed. Sinovac must submit its 2024 annual report (Form 20-F) and interim reports for Q2 2025 (Form 6-K) by May 11, 2026, or face possible delisting. The company appointed Zhonghua Certified Public Accountants for the audit on January 4 and says it will complete the required filings on time. Financial data show weak liquidity (current ratio 0.02) and diluted EPS of -0.03; market capitalization is USD 38.95 million and the share price is USD 0.12. » More on de.investing.com
Antigua court affirms Sinovac board until 2026 trial

The High Court of Antigua ordered that Sinovac’s current eight-member board remain in office until a court hearing scheduled for late April/early May 2026. The move follows petitions by several shareholders after a contested extraordinary general meeting and comes at a time when Sinovac’s financial position is rated weak by InvestingPro. The board aims to push for the resumption of NASDAQ trading, complete the audit with new auditors, and appeal a delisting notice. Investors should watch the company’s financial challenges, dividend claims from independent shareholders, and the upcoming court case. » More on de.investing.com
Sinovac faces delisting from NASDAQ after late filing of annual report

Sinovac received a delisting notice from NASDAQ because the 2024 annual report was not filed by the extended deadline of November 11. The securities would be suspended at the open of trading on November 21 and removed from the exchange unless the company requests a hearing by November 19; Sinovac said it would contest the move and seek an extension. In response, Sinovac appointed UHY LLP as its new auditor and is working to finalize the filings, but with only $38.1 million in market capitalization, a share price of $0.10 and weak metrics it is under considerable pressure. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Sinovac Biotech has already paid €46.86 in dividends. The last payout was in July 2025.

Financials

In the last year, Sinovac Biotech had revenue of €329.01m and net profit of -€50.87m

(EUR)	2025	YoY
Revenue	329.01m	5.26%
Gross profit	223.29m	5.29%
Net profit	-50.87m	158.23%
EBITDA	-159.94m	54.98%

Fundamentals

Metric	Value
Market capitalization	€421.77m
Number of shares	71.86m
52-week high/low	€5.87 - €5.87
Dividends	No
Beta	0.00
P/E ratio	-7.80
PEG ratio	-0.08
P/B ratio	0.10
P/S ratio	1.20

Company profile

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.